1. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children
- Author
-
Marisol Simões, Olindo Assis Martins-Filho, Akira Homma, Vasconcelos Pfc, Lis Ribeiro do Valle Antonelli, Christiane Costa-Pereira, Ana Carolina Campi-Azevedo, Ribeiro Jgl, Laise Rodrigues Reis, Cristina Toscano Fonseca, Pedro Luiz Tauil, Mambrini Jvm, Maia Mls, Peruhype-Magalhães, Camacho Lab, Romano Apm, Iramaya Rodrigues Caldas, Andréa Teixeira-Carvalho, Reinaldo de Menezes Martins, Elaine M. Souza-Fagundes, de Noronha Tg, Freire Mds, da Costa-Rocha Ia, Carla Magda Allan Santos Domingues, de Lima Smb, Lemos Jac, and Jordana Graziela Coelho-dos-Reis
- Subjects
0301 basic medicine ,Male ,Cellular immunity ,CD8-Positive T-Lymphocytes ,Antibodies, Viral ,Persistence (computer science) ,0302 clinical medicine ,17DD vaccine ,Immunology and Allergy ,Medicine ,Child ,Original Research ,Anticorpos Neutralizantes ,Imunidade Celular ,B-Lymphocytes ,Booster (rocketry) ,Yellow fever ,Vaccination ,Yellow Fever Vaccine ,Mem?ria celular ,Child, Preschool ,Female ,Yellow fever virus ,lcsh:Immunologic diseases. Allergy ,Immunology ,Vacina 17DD ,Immunization, Secondary ,cellular memory ,yellow fever ,03 medical and health sciences ,children ,Immunity ,Humans ,neutralizing antibodies ,Febre Amarela ,Seroconversion ,business.industry ,Infant ,medicine.disease ,Antibodies, Neutralizing ,Regimen ,Vacina??o ,030104 developmental biology ,Cross-Sectional Studies ,V?rus da Febre Amarela / patogenicidade ,business ,lcsh:RC581-607 ,030215 immunology - Abstract
Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais (FAPEMIG), BioManguinhos/FIOCRUZ, PROEP/IRR/FIOCRUZ, Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico-CNPq Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Universidade Federal de Minas Gerais. Departamento de Fisiologia e Biof?sica. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil Secretaria Municipal de Sa?de de Belo Horizonte. Belo Horizonte, MG, Brasil. Secretaria do Estado de Sa?de de Minas Gerais. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Escola Nacional de Sa?de P?blica Sergio Arouca. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil. Universidade de Bras?lia. Faculdade de Medicina. Bras?lia, DF, Brasil. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Instituto Evandro Chagas. Ananindeua, PA, Brasil. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Departamento de Imuniza??o e Doen?as Transmiss?veis. Bras?lia, DF, Brasil. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Programa Nacional de Imuniza??es. Bras?lia, DF, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil. The Yellow Fever (YF) vaccination is recommended for people living in endemic areas and represents the most effective strategy to reduce the risk of infection. Previous studies have warned that booster regimens should be considered to guarantee the long-term persistence of 17DD-YF-specific memory components in adults living in areas with YF-virus circulation. Considering the lower seroconversion rates observed in children (9-12 months of age) as compared to adults, this study was designed in order to access the duration of immunity in single-dose vaccinated children in a 10-years cross-sectional time-span. The levels of neutralizing antibodies (PRNT) and the phenotypic/functional memory status of T and B-cells were measured at a baseline, 30-45 days, 1, 2, 4, 7, and 10 years following primary vaccination. The results revealed that a single dose induced 85% of seropositivity at 30-45 days and a progressive time-dependent decrease was observed as early as 2 years and declines toward critical values (below 60%) at time-spans of ?4-years. Moreover, short-lived YF-specific cellular immunity, mediated by memory T and B-cells was also observed after 4-years. Predicted probability and resultant memory analysis emphasize that correlates of protection (PRNT; effector memory CD8+ T-cells; non-classical memory B-cells) wane to critical values within ?4-years after primary vaccination. Together, these results clearly demonstrate the decline of 17DD-YF-specific memory response along time in children primarily vaccinated at 9-12 months of age and support the need of booster regimen to guarantee the long-term persistence of memory components for children living in areas with high risk of YF transmission.
- Published
- 2019